{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:08:36Z","timestamp":1773151716368,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2002,5,3]],"date-time":"2002-05-03T00:00:00Z","timestamp":1020384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Head &amp; Neck"],"published-print":{"date-parts":[[2002,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The appropriate treatment approach for patients with T2N0 laryngeal cancer remains highly controversial. Because radiotherapy alone is associated with a high risk of local recurrence, we have developed a triple combination treatment approach consisting of 5\u2010fluorouracil (250 mg\/day, i.v.), vitamin A (50,000 unit\/day, i.m.) and external radiation (2.0 Gy\/day), which we have termed \u201cFAR therapy.\u201d<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with T2N0 glottic carcinoma were initially treated with 15 days of FAR therapy, which included a cumulative radiation dose of 30Gy (i.e., \u201c30 Gy of FAR therapy\u201d). Those patients who demonstrated a complete response either clinically or pathologically continued to receive further FAR therapy, with up to 60\u201370 Gy. All other patients received laryngectomy without any additional treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety\u2010five patients were treated according to this program, and most of the patients (98%) were able to complete this treatment course. Eighty\u2010eight patients (93%) were treated with FAR therapy alone. The local control and ultimate local control rates were 91% (85 of 93), and 99% (92 of 93), respectively. The cumulative 5\u2010year voice preservation and complete laryngeal preservation rates were 91% and 87%, respectively. The cumulative 5\u2010year disease\u2010specific survival rate was 97%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Because a high rate of laryngeal preservation was achieved without compromising disease\u2010specific survival, our treatment approach based on FAR therapy may be promising for the treatment of patients with T2N0 glottic carcinoma. \u00a9 2002 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/hed.10114","type":"journal-article","created":{"date-parts":[[2002,10,6]],"date-time":"2002-10-06T11:34:39Z","timestamp":1033904079000},"page":"637-642","source":"Crossref","is-referenced-by-count":25,"title":["\u201cFAR\u201d chemoradiotherapy improves laryngeal preservation rates in patients with T2N0 glottic carcinoma"],"prefix":"10.1002","volume":"24","author":[{"given":"Yoshihiko","family":"Kumamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muneyuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Kuratomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Toh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shinokuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Chujo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohtaro","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850501)55:9 <2058::AID-CNCR2820551405>3.0.CO;2-A"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910201)67:3<577::AID-CNCR2820670309>3.0.CO;2-W"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2890100603"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0347(199903)21:2<116::AID-HED4>3.0.CO;2-8"},{"key":"e_1_2_6_6_2","volume-title":"Otolaryngology head & neck surgery","author":"Cummings CW","year":"1996"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106133242402"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.890"},{"issue":"12","key":"e_1_2_6_9_2","first-page":"3258","article-title":"Potentiation of bleomycin by an antifungal polyene, pentamycin, in transformed animal cells","volume":"34","author":"Nakashima T","year":"1974","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_2_6_10_2","first-page":"85","article-title":"Enhancement of radiation effect on transformed flbroblastic cells by a synergistic combination of 5\u2010fluorouracil and polyenes in vitro","volume":"65","author":"Komiyama S","year":"1974","journal-title":"Gann"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000225299"},{"issue":"2","key":"e_1_2_6_12_2","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1016\/S0385-8146(85)80066-3","article-title":"Synergistic combination therapy of 5\u2010fluorouracil, vitamin A, and cobalt\u201060 radiation for head and neck tumors\u2014antitumor combination therapy with vitamin A","volume":"12","author":"Komiyama S","year":"1985","journal-title":"Auris Nasus Larynx"},{"issue":"4","key":"e_1_2_6_13_2","first-page":"92l","article-title":"Enhancement of the antitumor effects of 1,3\u2010bis(2\u2010chloroethyl)\u20101\u2010nitrosourea and cyclophosphamide by vitamin A","volume":"48","author":"Cohen MH","year":"1972","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_6_14_2","volume-title":"UICC TNM Classification of malignant tumors","author":"Hermanek P","year":"1992"},{"issue":"6","key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1200\/JCO.1997.15.6.2394","article-title":"Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx","volume":"15","author":"Mendenhall WM","year":"1997","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<40::AID-CNCR6>3.0.CO;2-V"}],"container-title":["Head &amp; Neck"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhed.10114","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hed.10114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:13:49Z","timestamp":1700392429000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hed.10114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5,3]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1002\/hed.10114"],"URL":"https:\/\/doi.org\/10.1002\/hed.10114","archive":["Portico"],"relation":{},"ISSN":["1043-3074","1097-0347"],"issn-type":[{"value":"1043-3074","type":"print"},{"value":"1097-0347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,5,3]]}}}